Deborah Dunsire, Lundbeck CEO
November 12, 2021 07:04 AM ESTUpdated 07:19 AM
Pharma

Cit­ing mi­graine drug growth and pan­dem­ic, Lund­beck to cut 300 jobs and close In­dia fa­cil­i­ty

Max Gelman

Senior Editor

The Dan­ish bio­phar­ma Lund­beck has seen its fair share of R&D set­backs over the years but it’s tak­en pride in Vyep­ti, the CGRP mi­graine drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Pfiz­er hires ex-FDA deputy Pa­trizia Cavaz­zoni as chief med­ical of­fi­cer

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Sanofi, Te­va bol­ster case for IBD drug with Phase 2 da­ta, de­spite po­ten­tial com­pe­ti­tion

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times